BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)

Historical Holders from Q1 2014 to Q1 2025

Symbol
BCRX on Nasdaq
CUSIP
09058V103
Type / Class
Equity / Common Stock
Shares outstanding
208M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
168M
Holdings value
$1.26B
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
254
Number of buys
100
Number of sells
-121
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.4% $141M 17.5M BlackRock, Inc. Mar 31, 2025

Institutional Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock (BCRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 822K $6.16M +$280K $7.50 20
2024 Q4 168M $1.26B -$35.9M $7.52 254
2024 Q3 172M $1.31B -$17.3M $7.60 256
2024 Q2 174M $1.08B -$19.8M $6.18 238
2024 Q1 179M $908M +$13.5M $5.08 235
2023 Q4 177M $1.06B -$53.9M $5.99 233
2023 Q3 175M $1.24B +$20.6M $7.08 227
2023 Q2 173M $1.22B +$8.68M $7.04 231
2023 Q1 171M $1.42B +$92.1M $8.34 236
2022 Q4 156M $1.79B +$88.2M $11.48 222
2022 Q3 147M $1.85B -$41.6M $12.60 213
2022 Q2 146M $1.55B +$166M $10.58 201
2022 Q1 127M $2.06B +$166M $16.26 214
2021 Q4 118M $1.62B +$193M $13.85 195
2021 Q3 103M $1.48B -$24.1M $14.37 193
2021 Q2 105M $1.65B +$17.8M $15.81 190
2021 Q1 104M $1.06B -$140M $10.17 182
2020 Q4 121M $898M -$44.5M $7.45 171
2020 Q3 127M $438M -$23.5M $3.44 148
2020 Q2 131M $624M +$86.6M $4.76 155
2020 Q1 123M $245M -$37.6M $2.00 127
2019 Q4 136M $471M +$129M $3.45 126
2019 Q3 97.2M $279M -$6.77M $2.87 105
2019 Q2 99.8M $378M -$88.3M $3.79 109
2019 Q1 101M $821M -$625K $8.14 126
2018 Q4 101M $815M +$8.36M $8.07 115
2018 Q3 100M $764M +$74.2M $7.63 108
2018 Q2 87.4M $501M -$8.95M $5.73 96
2018 Q1 89M $425M -$6.56M $4.77 97
2017 Q4 90.3M $443M +$31.9M $4.91 110
2017 Q3 83.6M $436M +$74.6M $5.24 115
2017 Q2 68.7M $382M +$5.09M $5.56 109
2017 Q1 67.6M $566M +$138M $8.40 113
2016 Q4 58.4M $370M +$11.8M $6.33 107
2016 Q3 56.5M $249M +$24.6M $4.41 97
2016 Q2 51.2M $145M -$10.4M $2.84 89
2016 Q1 53.9M $152M -$59.5M $2.83 98
2015 Q4 63M $650M -$41.8M $10.32 116
2015 Q3 63.7M $726M +$33.9M $11.40 121
2015 Q2 62.2M $929M +$39.2M $14.93 119
2015 Q1 58M $524M +$37.8M $9.03 95
2014 Q4 53.7M $652M +$25.6M $12.16 87
2014 Q3 56.7M $554M -$6.98M $9.78 100
2014 Q2 49.8M $635M +$146M $12.75 98
2014 Q1 43.5M $460M +$93.2M $10.58 85